In November 1935 at Lisbon’s Santa Marta Hospital, Portuguese neurologist António Egas Moniz drilled into the skulls of his first twenty psychiatric patients, severing the white-matter tracts of the frontal lobes, and reported — on the basis of a few weeks of observation and no controls — that he had cured or improved most of them; the gap between that claim and the documented reality is the entire case. The reality was a procedure that, in its American form, lobotomized roughly 40,000 to 50,000 people, blunted or destroyed the personalities of a large fraction of them, killed on the order of one in twenty, and was performed most heavily on women, the institutionalized, children, and the powerless who could not consent. It was not validated against a sham, not measured against an inert comparator, not followed over the years it would have taken to see what it did; it was launched on the authority of a respected clinician working fast in a field that had nothing else to offer overcrowded asylums.
The operation did not fail quietly in a backwater. It was crowned. Moniz received the 1949 Nobel Prize in Physiology or Medicine “for his discovery of the therapeutic value of leucotomy in certain psychoses,” the only Nobel ever awarded for a surgical destruction of healthy brain tissue. That prize functioned as a regulatory and reputational green light: it converted an undertested operation into a respectable standard of care and supercharged its American evangelist, neurologist Walter Jackson Freeman II, who by the late 1960s had performed or supervised more than 3,500 lobotomies — a death toll among his own patients estimated at roughly 490.
Freeman’s signature innovation was to remove the operating room entirely. His “transorbital” or “ice-pick” lobotomy, first performed on a living patient on January 17, 1946, drove a leucotome through the thin bone of the eye socket and swept it across the frontal lobes, often in under ten minutes, frequently with no surgeon present and no general anaesthetic — he stunned patients with electroshock instead. He performed it on minors, on patients with headaches and depression, and on Rosemary Kennedy in 1941, who was left permanently incapacitated. The surrogate endpoint — a calmer, more “manageable” ward patient — was achieved. The actual endpoint — a recovered human being — usually was not.
The reckoning came not from a tribunal but from a molecule. Chlorpromazine, synthesized in 1950 and shown to control psychosis by 1952, offered the same institutional benefit — quieter, more tractable patients — without drilling through the skull. Within roughly a decade the lobotomy collapsed from a Nobel-honored frontier therapy to a byword for medical hubris. It was never recalled, never banned by a single statute; it was simply abandoned, made obsolete by a pill, and is now the textbook case of how prestige, a flattering surrogate measure, and an absence of controlled evidence can scale a mutilating procedure to tens of thousands before anyone is required to prove it works.
In 1957 surgeon J. Roderick Kitchell and colleagues at Presbyterian Hospital in Philadelphia, following an Italian lead, began tying off the internal mammary arteries in the chests of angina patients and reporting that roughly two-thirds felt better — and the gap between that reported relief and the operation’s actual physiological effect is the entire case, because the operation did almost nothing the body could measure. The procedure was supposed to relieve the crushing chest pain of coronary disease by occluding the internal mammary arteries so that blood would be diverted into the heart muscle. It was simple, it was fast, it was performed under local anaesthetic, and within two or three years it had been carried out on thousands of patients across Italy and the United States on the strength of uncontrolled before-and-after testimonials.
The reported numbers looked persuasive: in the largest case series, on the order of two-thirds to three-quarters of patients said their angina improved, many dramatically, with effects holding up over months and years of follow-up. What no one had done was ask whether the cut, rather than the ligature, was doing the work. Angina is a subjective, fluctuating symptom, and the act of being operated on by a confident surgeon is among the most powerful placebos in medicine.
The reckoning was unusually clean and unusually fast. Between 1959 and 1960 two small randomized trials — Leonard A. Cobb’s group at the University of Washington and E. Grey Dimond’s at the University of Kansas — did something no surgical evaluation had done before: they randomized angina patients to either the real ligation or a sham operation, an identical skin incision in which the arteries were exposed but left intact, with neither the patient nor the assessing physician knowing which had been done. The sham patients improved exactly as much as the ligated ones. The exercise electrocardiograms were unchanged by either operation. The benefit was real to the patients and entirely placebo in origin.
The operation was abandoned almost immediately — not banned by any agency, not litigated, but disproven and quietly dropped. Its lasting legacy is the opposite of its intended one: internal mammary artery ligation is now the founding textbook example of why surgery, like a drug, must be tested against a placebo, and of how a self-limiting subjective symptom plus an enthusiastic operator can manufacture thousands of “cures” out of nothing but expectation and a scar.
In May 1962, University of Minnesota surgical chairman Owen H. Wangensteen announced in JAMA that a duodenal ulcer could be cured without an operation by swallowing a balloon and chilling the stomach to roughly minus-10 degrees Celsius — a bloodless “physiological gastrectomy” — and within two years thousands of Americans had been frozen on refrigeration machines that had never passed a single controlled trial; the gap between that announcement and the 1969 finding that a fake freeze worked exactly as well is the entire case. Gastric freezing was not a fringe quackery. It was launched by one of the most decorated academic surgeons in the United States, published in the country’s leading medical journal, and adopted at scale before anyone tested it against a placebo.
The promise rested on a plausible mechanism and a flattering measure. Wangensteen reasoned that supercooling the gastric mucosa would knock out the acid-secreting cells that drove ulcer disease, achieving by cold what surgeons then achieved by cutting out half the stomach. Early uncontrolled series were spectacular: investigators reported that on the order of 85 percent of patients had prompt relief of pain and apparent healing of ulcer craters. That surrogate — short-term symptom relief, the most placebo-responsive endpoint in all of medicine — was mistaken for cure. The acid suppression was real but transient, returning to baseline within weeks to months, and the symptom relief was, it later emerged, almost entirely the patient’s own expectation.
The reckoning came from the design that the launch had skipped. By 1964 controlled and double-blind studies were appearing, and in July 1969 a multi-institution cooperative trial led by Julian Ruffin reported in the New England Journal of Medicine that patients given a genuine gastric freeze did no better than patients given a sham freeze in which the same balloon circulated fluid that was never chilled. The treatment effect, against a proper control, was zero. Gastric freezing collapsed almost as fast as it had spread. It was never banned and never recalled; it was abandoned — and it survives in textbooks as the canonical demonstration of why a new procedure must be tested against a sham before, not after, it is sold to thousands.
The regimen that German obstetricians Bernhardt Krönig and Carl Joseph Gauss perfected at the Freiburg women’s clinic from 1906, and that an American feminist crusade exported to U.S. hospitals from June 1914, promised “painless childbirth” — and the entire case lives in the fact that it never delivered painlessness at all. The injection of scopolamine and morphine did not abolish the agony of labor; it abolished the patient’s memory of it. Women still felt every contraction and still screamed and thrashed through them; scopolamine merely erased the recollection afterward, so that a mother who had been strapped to a padded “crib” bed for hours, blindfolded and plugged with cotton, woke believing she had slept through a miracle. The surrogate endpoint — a patient who reported no memory of pain — was achieved. The actual endpoint — a labor that was safe and painless — was not.
The harms were two-fold and physical. The mothers, delirious from scopolamine, became so disoriented and combative that obstetricians routinely restrained them with leather straps to a screened crib-bed, gauze over the eyes and wadding in the ears, so they could not injure themselves during the thrashing the drug induced. The newborns, whose blood took up the morphine that freely crossed the placenta, were born sedated — flaccid, cyanotic, with depressed reflexes and suppressed breathing, exposed to asphyxia and sometimes requiring resuscitation that early-twentieth-century obstetrics could not reliably provide.
What carried Twilight Sleep was not obstetric data but a consumer movement. A June 1914 McClure’s Magazine article, “Painless Childbirth,” by Marguerite Tracy and Constance Leupp, triggered thousands of letters; Manhattan suffragists founded the National Twilight Sleep Association that year and campaigned through the New York Times, the Ladies’ Home Journal, and lecture halls, framing the right to forget labor as a feminist demand. The reckoning was equally a matter of public sentiment. In August 1915 one of the movement’s own leading advocates, Mrs. Frances X. Carmody of Brooklyn, died of hemorrhage delivering her third child under Twilight Sleep at Long Island College Hospital; her physician and husband insisted the drugs were blameless, but the symbol was lethal to the cause, and demand collapsed within roughly fifteen months.
No statute banned it. The combination simply could not be administered safely outside the quiet, individualized, heavily-staffed Freiburg setting, and once safer regional and inhalational analgesia matured, the regimen was abandoned as a relic — a textbook case of an intervention validated by the memory of the patient rather than by her safety or her child’s.
For roughly the first three-quarters of the twentieth century, tonsillectomy was the most frequently performed operation in the United States — a near-compulsory rite of childhood scheduled on the order of a million-plus times a year for sore throats, “mouth breathing,” poor appetite, and the vague proposition that a child would simply be healthier without tonsils; the gap between that universal promise and the evidence is the entire case, because the operation was never shown to deliver the broad benefits claimed, killed a measurable number of the children it was sold to protect, and for a period in the 1940s demonstrably raised the risk of paralytic polio. At its 1959 peak roughly 1.4 million tonsillectomies were performed annually in the U.S., the overwhelming majority on children, and by mid-century an estimated 30 percent of American children had lost their tonsils — many to surgeons who, examined honestly, could not say why.
The procedure rode the “focal infection” theory: the early-twentieth-century belief that lurking pockets of chronic infection in the tonsils seeded disease throughout the body and were best excised pre-emptively. On that theory the indication became, in practice, the mere possession of tonsils. The surrogate that justified the knife was not a measured health outcome but a clinical impression — the tonsils “looked enlarged” — and impressions, it turned out, were nearly random. In 1934 the American Child Health Association sent 1,000 New York schoolchildren through successive examinations and found 61 percent had already been tonsillectomized; of the remaining 39 percent, physicians recommended surgery for all but 65, then for nearly half of those who had just been cleared, and again for nearly half of that residue — a recursive demonstration that the indication lived in the examiner, not the child.
The disconfirming evidence accumulated for forty years before the practice yielded. James Alison Glover’s 1938 study showed English tonsillectomy rates varying by an order of magnitude between districts with no relation to disease — the founding observation of “unwarranted variation,” still called the Glover phenomenon. From 1942 onward, epidemiologists documented that children tonsillectomized shortly before exposure to poliovirus suffered the deadly bulbar form at multiples of the background rate. And in 1984 the first rigorous randomized trial, by Jack Paradise in the New England Journal of Medicine, found a real but narrow benefit only for the most severely and frequently infected children — a tiny slice of those who had been operated on for decades. The operation was not banned. It was restricted, its indications tightened, its volume cut by more than half, retired from routine use by evidence that arrived long after the harm.
On October 30, 1967, in Zurich, the neurosurgeon M. Gazi Yaşargil sutured a scalp artery to a cortical branch of the middle cerebral artery under the operating microscope, rerouting blood around a blocked vessel to feed a starving brain; the operation was elegant, technically dazzling, and — for the prevention of stroke in patients with carotid and middle-cerebral disease — almost entirely unproven, and that gap between surgical beauty and clinical benefit is the entire case. For nearly two decades the extracranial-intracranial (EC-IC) arterial bypass spread on the strength of its own plausibility and on case series reporting open grafts, until a single randomized trial showed it prevented nothing it claimed to prevent.
The operation was never a fraud and never a mass killer in the lobotomy sense. It killed and disabled quietly, at the margins: a procedure with a roughly 12 percent thirty-day rate of stroke or death imposed up front on patients who, the trial would show, were no better protected afterward. The surrogate that sustained it was graft patency — the bypass stayed open in about 96 percent of cases, a number surgeons and angiograms could see and celebrate. A patent vessel looked like a prevented stroke. It was not the same thing, and conflating the two is the mechanism that kept the operation alive.
The reckoning arrived not from a regulator or a court but from an eight-year, NIH-funded randomized controlled trial led by the Canadian neurologist Henry J. M. Barnett of London, Ontario. Published in the New England Journal of Medicine on November 7, 1985, the International EC/IC Bypass Study randomized 1,377 patients at 71 centers in 14 countries and found that surgery added to best medical care did not reduce fatal or nonfatal stroke; two subgroups — patients with severe middle-cerebral stenosis and those with persisting symptoms after carotid occlusion — actually fared worse with the operation. Within a few years the procedure collapsed from a flourishing subspecialty to a narrow, rarely-indicated salvage technique. It was not banned. It was disconfirmed, and it became one of medicine’s foundational lessons in why a trial must precede an operation, not follow it.